SS Innovations International, Inc. (NASDAQ: SSII) has reported significant growth in the adoption of its SSi Mantra surgical robotic system, according to a recent press release. As of September 8, 2026, the company has completed 14,103 cumulative procedures, a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems has also expanded by 42%, reaching 238 units across 12 countries, up from 168 systems previously. This expansion underscores the growing global demand for affordable robotic surgery solutions.
Approximately 1,500 physicians have been trained on the SSi Mantra platform, which has now been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the system's versatility and its potential to improve surgical outcomes in diverse healthcare settings.
In addition, SS Innovations reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31. Notably, a telesurgery was performed over a distance of more than 13,600 miles between Colombia and India, demonstrating the platform's capability for remote surgery. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system's efficiency and reliability.
Looking forward, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes it can obtain European Union CE marking certification by year-end 2026. These regulatory milestones are critical for expanding into major markets and could significantly boost the company's growth trajectory.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the SSi Mantra surgical robotic system and the SSi Mudra suite of surgical instruments, which support a variety of procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective solutions.
For investors, the latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. The full report can be viewed at https://ibn.fm/DJILj. InvestorWire, a specialized communications platform, provides wire-grade press release syndication and is part of the Dynamic Brand Portfolio @ IBN. More information is available at https://www.InvestorWire.com.
The growth in procedures and installations signals increasing acceptance of robotic surgery in emerging markets, where access to advanced medical technology has traditionally been limited. SS Innovations' progress could disrupt the surgical robotics market by offering a cost-effective alternative to established players. The upcoming regulatory decisions in the U.S. and Europe will be pivotal in determining the company's ability to compete globally. For healthcare providers and patients, the expansion of SSi Mantra may lead to more accessible and advanced surgical care. As the company continues to train physicians and accumulate clinical data, its impact on the global surgical landscape is likely to grow.
